Healthcare Services

Healthcare In-Vitro Diagnostics: What Comes After COVID

Published 5 min read Acuitas Health Analytics

Healthcare In-Vitro Diagnostics: What Comes After COVID

In-vitro diagnostics (IVD) are tests done on samples taken from the body, such as blood, urine or swabs. They include lab analysers, rapid tests, molecular tests and the reagents they use. COVID-19 made IVD a household term. Now the industry is adjusting to life after the pandemic peak.

After the COVID peak

The Lancet Commission on diagnostics noted that early problems with COVID-19 tests slowed the response, and unreliable or even false tests appeared quickly [2]. Rich countries scaled up testing through public and private labs. Many low- and middle-income countries could not reach full capacity [2]. When COVID testing fell, many labs were left with new machines and trained staff. Using this for other diseases is one of the main post-COVID opportunities.

The access gap remains

About 47% of the world's population still has little or no access to diagnostics [1]. Up to 81% of basic primary care facilities in 14 low- and middle-income countries lack essential tests, excluding HIV and malaria [3].

Share of new TB cases by WHO region, 2024 (%)South-East Asia34%Western Pacific27%Africa25%
Source: WHO fact sheet on tuberculosis [5].

Growth areas

  • Chronic disease: diabetes, kidney and heart tests, as populations age.
  • Infectious disease: TB, HIV, hepatitis and drug-resistance testing.
  • Cancer: screening, tumour gene tests and liquid biopsies.
  • Point of care and home testing: faster answers outside the lab.
  • Brain health: blood tests for Alzheimer's, such as the first FDA-cleared test in 2025 [4].

Molecular tests

Molecular testing grew fastest during COVID-19. It is now used for TB, HIV viral load, HPV and many other infections. WHO recommends rapid tests, including molecular ones, as the first test for anyone with signs of TB [5]. TB caused 1.23 million deaths in 2024 [5]. Cancer care also relies more on molecular tests, to pick targeted treatments.

Antibiotic resistance

WHO reports that 1 in 6 lab-confirmed bacterial infections was resistant to antibiotics in 2023 [6]. Tests that identify bacteria and their resistance faster help doctors use the right antibiotic. WHO's global AMR plan puts stronger labs and surveillance at its core [6].

Regulation

Rules for IVD are getting stricter in many regions, especially after the flood of poor-quality COVID tests. Makers now need stronger proof of performance. This raises costs but should improve trust in results.

Key numbers at a glance

  • 47% of people have little or no access to diagnostics.
  • Up to 81% of primary care sites in 14 countries lack essential tests.
  • 1 in 6 bacterial infections resistant (2023).
  • TB: 1.23 million deaths in 2024.

Go deeper

Want the full picture? Our report covers market size, growth, segments, countries and the key companies. Read the report or get a free sample.

TB, HIV and hepatitis drive demand

In 2024, TB made 10.7 million people ill [5]. About 87% of new cases were in 30 high-burden countries [5]. WHO recommends rapid tests for everyone with TB symptoms [5]. Programmes for HIV and hepatitis also rely on regular testing, for diagnosis and to check treatment. These public health programmes buy large volumes of tests and shape prices.

Chronic disease testing

Chronic diseases need regular blood and urine tests: blood sugar and HbA1c for diabetes, kidney tests, cholesterol and liver tests. As people live longer with several conditions, test volumes rise steadily. This is one of the most stable parts of IVD demand.

Where testing happens is changing

  • Central labs handle high volumes at low cost per test.
  • Hospital labs cover urgent tests around the clock.
  • Clinics and pharmacies use point-of-care tests.
  • Homes use self-tests for some conditions.

Makers increasingly offer the same test in several formats, to fit each setting.

Supply and local production

During COVID-19, many countries struggled to get tests because supply was concentrated in a few places. The Lancet Commission called for developing diagnostics beyond high-income countries [2]. Regional manufacturing and shared buying can make supply more reliable.

Where to read more

All figures in this article come from public sources listed below. For more detail, start with the Lancet Commission on diagnostics, WHO's Global Diagnostics Coalition and the WHO fact sheets on tuberculosis and antimicrobial resistance. Each is free to read online. Health planners, lab managers and buyers can use these sources to compare their own country or facility with the global picture. If anything here raises a question about your own health, take this article to your doctor or pharmacist and talk it through together. Good questions lead to better care.

Cancer testing

Cancer is a fast-growing area of IVD. WHO lists the HPV test as the preferred way to screen for cervical cancer [7]. A correct diagnosis is essential because every cancer type needs its own treatment [7]. Tumour gene tests now guide many targeted drugs. Blood tests that look for cancer DNA, called liquid biopsies, are being studied for early detection and follow-up.

More numbers

  • 47% of people have little or no access to diagnostics.
  • TB: 10.7 million cases in 2024.
  • 87% of new TB cases in 30 high-burden countries.

Questions for buyers

  • Is the test approved and quality-assured here?
  • How does its accuracy compare with the reference test?
  • What does each test really cost, including controls and staff time?
  • Can results flow into our records system?

What this means

After the COVID spike, IVD growth now rests on steady needs: chronic disease, infections, cancer and ageing. The largest unmet need is in primary care in low- and middle-income countries. Makers that offer affordable, quality-assured tests for these settings have the biggest room to grow.

Explore on Acuitas

Topics: Diagnostics and lab testing

Sources

  1. Fleming KA et al. The Lancet Commission on diagnostics: transforming access to diagnostics (The Lancet, 2021)
  2. The Lancet press release (Oct 2021): Half of the global population lack access to basic diagnostics
  3. WHO: Global Diagnostics Coalition
  4. US FDA (16 May 2025): FDA clears first blood test used in diagnosing Alzheimer's disease
  5. WHO fact sheet: Tuberculosis
  6. WHO fact sheet: Antimicrobial resistance
  7. WHO fact sheet: Cancer

Banner image: Лабораторни епруветки. Laboratory test tubes by Stoyko Sabotanov, CC BY 4.0, via Wikimedia Commons.

Topics: Diagnostics and lab testing

Back to Blog